The primary focus of this project is to elucidate the structure and function of the receptor for three classes of calcium channel inhibitor drugs, viz., DIHYDROPYRIDINES, (e.g., nifedipine), PHENYLALKYLAMINES (e.g., verapamil), and BENZOTHIAZEPINES (e.g., diltiazem) in heart, vascular smooth muscle and brain. These drugs are used to treat coronary artery disease and hypertension and may be valuable in related conditions such as cerebral vasospasm. The drug binding sites are located in specific domains of a large protein, the alpha 1 subunit of the L type voltage-dependent calcium channel (VDCC). The central hypothesis is that tissue-specific alpha 1 isoforms contain the drug binding domains and form the calcium channel. Other subunits, however, may be required for function and regulation. The three specific aims are: (1) to isolate and sequence full-length alpha 1 cDNA clones from heart, vascular smooth muscle and brain; (2) to express VDCC activity with appropriate pharmacology using alpha 1 cDNA clones alone or in combination with cDNA clones encoding the other VDCC subunits; (3) to identify the drug binding domains and the sites for regulation of VDCC within the alpha 1 subunit. Skeletal muscle alpha 1 cDNAs have been isolated and sequenced (skeletal muscle T-tubules are the richest source of VDCC and calcium antagonist binding sites) and will be used to identify alpha 1 isoforms in other tissues. The alpha 1 subunit alone or in combination with other subunits will be expressed in Xenopus oocytes and/or mammalian cells. Function of the expressed protein(s) will be examined using radioligand binding and electrophysiological techniques. Based upon deduced primary amino acid sequence of the alpha 1 isoforms and the known tissue-specific pharmacological characteristics, chimeric constructs and selected mutants will be made, expressed and functionally evaluated for VDCC activity and pharmacology. These proposed studies are relevant to understanding the nature of the receptors for, and hence, bear on the mechanism of the calcium antagonists. Further, if VDCC are altered in certain cardiovascular disorders as has been suggested by published studies, the nature of the putative defects can be explored by genetic means. The data derived from the proposed experiments should be useful in understanding the function and regulation of the receptor and of channel activity.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37HL043231-07
Application #
2220948
Study Section
Special Emphasis Panel (NSS)
Project Start
1989-07-01
Project End
1999-06-30
Budget Start
1995-07-01
Budget End
1996-06-30
Support Year
7
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Cincinnati
Department
Pharmacology
Type
Schools of Medicine
DUNS #
City
Cincinnati
State
OH
Country
United States
Zip Code
45221
Chang, W; Pratt, S A; Chen, T H et al. (2001) Parathyroid cells express dihydropyridine-sensitive cation currents and L-type calcium channel subunits. Am J Physiol Endocrinol Metab 281:E180-9
Motoike, H K; Bodi, I; Nakayama, H et al. (1999) A region in IVS5 of the human cardiac L-type calcium channel is required for the use-dependent block by phenylalkylamines and benzothiazepines. J Biol Chem 274:9409-20
Varadi, G; Strobeck, M; Koch, S et al. (1999) Molecular elements of ion permeation and selectivity within calcium channels. Crit Rev Biochem Mol Biol 34:181-214
Mikala, G; Klockner, U; Varadi, M et al. (1998) cAMP-dependent phosphorylation sites and macroscopic activity of recombinant cardiac L-type calcium channels. Mol Cell Biochem 185:95-109
Eisfeld, J; Mikala, G; Varadi, G et al. (1997) Inhibition of cloned human L-type cardiac calcium channels by 2,3-butanedione monoxime does not require PKA-dependent phosphorylation sites. Biochem Biophys Res Commun 230:489-92
Bahinski, A; Yatani, A; Mikala, G et al. (1997) Charged amino acids near the pore entrance influence ion-conduction of a human L-type cardiac calcium channel. Mol Cell Biochem 166:125-34
He, M; Bodi, I; Mikala, G et al. (1997) Motif III S5 of L-type calcium channels is involved in the dihydropyridine binding site. A combined radioligand binding and electrophysiological study. J Biol Chem 272:2629-33
Bodi, I; Yamaguchi, H; Hara, M et al. (1997) Molecular studies on the voltage dependence of dihydropyridine action on L-type Ca2+ channels. Critical involvement of tyrosine residues in motif IIIS6 and IVS6. J Biol Chem 272:24952-60
Klockner, U; Mikala, G; Eisfeld, J et al. (1997) Properties of three COOH-terminal splice variants of a human cardiac L-type Ca2+-channel alpha1-subunit. Am J Physiol 272:H1372-81
Klockner, U; Mikala, G; Schwartz, A et al. (1996) Molecular studies of the asymmetric pore structure of the human cardiac voltage- dependent Ca2+ channel. Conserved residue, Glu-1086, regulates proton-dependent ion permeation. J Biol Chem 271:22293-6

Showing the most recent 10 out of 33 publications